Sickle Cell Anemia Therapeutics Market Poised for Robust Growth - Projected to Hit USD 9.99 Billion by 2031 at 13.7% CAGR

QY Research has recently published a report, titled "Sickle Cell Anemia Therapeutics Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031". The global Sickle Cell Anemia Therapeutics market is comprehensively analyzed in the report with the main objective of providing accurate market data and useful recommendations to help players to gain strong growth in future. The report is compiled by subject matter experts and experienced market analysts, which makes it highly authentic and reliable. Readers are provided with deep analysis of historical and future market scenarios to get sound understanding of market competition and other important aspects. The report offers exhaustive research on market dynamics, key segments, leading players, and different regional markets. It is a complete package of thorough analysis and research on the global Sickle Cell Anemia Therapeutics market.

The global market for Sickle Cell Anemia Therapeutics was estimated to be worth US$ 4067 million in 2024 and is forecast to a readjusted size of US$ 9988 million by 2031 with a CAGR of 13.7% during the forecast period 2025-2031.

Get PDF Sample Copy of Report: (Including Full TOC, List of Tables & Figures, Chart) https://www.qyresearch.in/request-sample/pharma-healthcare-sickle-cell-anemia-therapeutics-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Sickle cell disease (SCD) is a chronic, inherited blood disorder caused by a mutation in the beta-globin gene, leading to the production of abnormal hemoglobin called sickle hemoglobin (HbS). Under low-oxygen conditions, HbS polymerizes, causing red blood cells to assume a rigid, sickle shape. These deformed cells are prone to hemolysis and can block blood vessels, resulting in pain, anemia, and organ damage. Therapeutic approaches include pharmacological treatments (e.g., hydroxyurea, L-glutamine), gene therapy, hematopoietic stem cell transplantation, and supportive care.

Global Sickle Cell Anemia Therapeutics key players include Emmaus Medical, Theravia, Gamida Cell, GlycoMimetics, etc. Americas is the largest market, with a share about 55%, followed by Europe, and Middle East & Africa, both have a share over 35 percent. In terms of product, Blood Transfusion is the largest segment, with a share over 35%. And in terms of application, the largest application is Child, followed by Adult.The therapeutic landscape for sickle cell disease is rapidly evolving, with major pharmaceutical players (e.g., Pfizer, Novartis, Novo Nordisk) investing alongside specialized biotech firms (e.g., Bluebird Bio, CRISPR Therapeutics, Imara, Emmaus Medical). Approved treatments range from small-molecule agents like L-glutamine (Emmaus) to gene-based curative approaches such as Bluebird's Zynteglo and CRISPR/Vertex's Casgevy, marking a shift toward durable, potentially one-time interventions.

Future development will prioritize expanding patient access to gene therapies, addressing long-term safety, and improving conditioning regimens for stem cell transplantation. Novel approaches, including anti-adhesion therapies (GlycoMimetics), nitric oxide modulators (Prolong), and macrophage-targeted solutions (Modus), are diversifying the pipeline. With ongoing clinical innovation and supportive regulatory momentum, the field is transitioning from symptomatic relief to functional cures, especially for underserved global populations.

Drivers and Restraints-

The report explains the drivers shaping the future of the Sickle Cell Anemia Therapeutics market. It evaluates the various forces that are expected to create a positive influence on the overall market. Analysts have studied the investments in research and development of products and technologies that are expected to give the players a definite boost. Furthermore, researchers have also included an analysis of the changing consumer behavior that is projected to impact the supply and demand cycles present in the global Sickle Cell Anemia Therapeutics market. Evolving per capita earnings, improving economic statuses, and emerging trends have all been studied in this research report.

The research report also explains the potential restraints present in the global Sickle Cell Anemia Therapeutics market. It evaluates the aspects that are likely to hamper the market growth in the near future. In addition to this assessment, it also provides a list of opportunities that could prove lucrative to the overall market. Analysts provide solutions for turning threats and restraints into successful opportunities in the coming years.

The competitive landscape of the global Sickle Cell Anemia Therapeutics market is broadly studied in the report with large focus on recent developments, future plans of top players, and key growth strategies adopted by them. The analysts authoring the report have profiled almost every major player of the global Sickle Cell Anemia Therapeutics market and thrown light on their crucial business aspects such as production, areas of operation, and product portfolio. All companies analyzed in the report are studied on the basis of vital factors such as market share, market growth, company size, production volume, revenue, and earnings.

Key Players Mentioned in the Global Sickle Cell Anemia Therapeutics Market Research Report:

Emmaus Medical
Theravia
Pfizer
Novartis
Bluebird Bio
Novo Nordisk
Gamida Cell
CRISPR Therapeutics
GlycoMimetics
Prolong Pharmaceuticals
Modus Therapeutics
Sangamo Biosciences
Bioverativ
Imara
Ironwood Pharmaceuticals

The report offers great insights into important segments of the global Sickle Cell Anemia Therapeutics market while concentrating on their CAGR, market size, market share, and future growth potential. The global Sickle Cell Anemia Therapeutics market is mainly segmented according to type of product, application, and region. Each segment in these categories is extensively researched to become familiar with their growth prospects and key trends. Segmental analysis is highly important to identify key growth pockets of a global market. The report provides specific information on the market growth and demand of different products and applications to help players to focus on profitable areas of the global Sickle Cell Anemia Therapeutics market.

Details of Sickle Cell Anemia Therapeutics Market Segmentation: -

Segment by Type:

Blood Transfusion
Pharmacotherapy
Bone Marrow Transplant

Segment by Application:

Child
Adult

Research Methodology

This report has been compiled using latest primary and secondary research methodologies such as data triangulation, qualitative and quantitative analysis, and top-down and bottom-up approaches. The researchers also referred to reliable secondary sources for collecting important data and statistics. All the findings of the research study have been verified and revalidated with the help of authentic primary sources.

The researchers create a unique model and customize it for each research study. Their market forecasts are based on the industry-best combination of domain expertise, industry knowledge and experience, technological analysis, and economic tools. Technological market models are generally adopted for long-term market forecasting, whereas econometric models are adopted for short-term forecasting. The researchers were provided with advanced analysis tools at the time of the preparation of the report.

Report Objectives

(1) To carefully analyze and estimate the size of the global Sickle Cell Anemia Therapeutics market

(2) To clearly segment the global Sickle Cell Anemia Therapeutics market and estimate the market size of the segments

(3) To provide details about key strategies adopted by leading players of the global Sickle Cell Anemia Therapeutics market

(4) To help readers understand current and future market scenarios

(5) To provide information about latest trends of the global Sickle Cell Anemia Therapeutics market and its key segments

(6) To assess the contribution of each region or country to the global Sickle Cell Anemia Therapeutics market

(7) To provide information on important drivers, restraints, and opportunities of the global Sickle Cell Anemia Therapeutics market

(8) To accurately calculate the market shares of key segments, regions, and companies in the global Sickle Cell Anemia Therapeutics market

Request Pre-Order Enquiry or Customized Research on This Report: https://www.qyresearch.in/pre-order-inquiry/pharma-healthcare-sickle-cell-anemia-therapeutics-market-share-and-ranking-overall-sales-and-demand-forecast-2025-2031

Table of Content

1 Market Overview
1.1 Sickle Cell Anemia Therapeutics Product Introduction
1.2 Global Sickle Cell Anemia Therapeutics Market Size Forecast (2020-2031)
1.3 Sickle Cell Anemia Therapeutics Market Trends & Drivers
1.3.1 Sickle Cell Anemia Therapeutics Industry Trends
1.3.2 Sickle Cell Anemia Therapeutics Market Drivers & Opportunity
1.3.3 Sickle Cell Anemia Therapeutics Market Challenges
1.3.4 Sickle Cell Anemia Therapeutics Market Restraints
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Competitive Analysis by Company
2.1 Global Sickle Cell Anemia Therapeutics Players Revenue Ranking (2024)
2.2 Global Sickle Cell Anemia Therapeutics Revenue by Company (2020-2025)
2.3 Key Companies Sickle Cell Anemia Therapeutics Manufacturing Base Distribution and Headquarters
2.4 Key Companies Sickle Cell Anemia Therapeutics Product Offered
2.5 Key Companies Time to Begin Mass Production of Sickle Cell Anemia Therapeutics
2.6 Sickle Cell Anemia Therapeutics Market Competitive Analysis
2.6.1 Sickle Cell Anemia Therapeutics Market Concentration Rate (2020-2025)
2.6.2 Global 5 and 10 Largest Companies by Sickle Cell Anemia Therapeutics Revenue in 2024
2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Sickle Cell Anemia Therapeutics as of 2024)
2.7 Mergers & Acquisitions, Expansion
3 Segmentation by Type
3.1 Introduction by Type
3.1.1 Blood Transfusion
3.1.2 Pharmacotherapy
3.1.3 Bone Marrow Transplant
3.2 Global Sickle Cell Anemia Therapeutics Sales Value by Type
3.2.1 Global Sickle Cell Anemia Therapeutics Sales Value by Type (2020 VS 2024 VS 2031)
3.2.2 Global Sickle Cell Anemia Therapeutics Sales Value, by Type (2020-2031)
3.2.3 Global Sickle Cell Anemia Therapeutics Sales Value, by Type (%) (2020-2031)
4 Segmentation by Application
4.1 Introduction by Application
4.1.1 Child
4.1.2 Adult
4.2 Global Sickle Cell Anemia Therapeutics Sales Value by Application
4.2.1 Global Sickle Cell Anemia Therapeutics Sales Value by Application (2020 VS 2024 VS 2031)
4.2.2 Global Sickle Cell Anemia Therapeutics Sales Value, by Application (2020-2031)
4.2.3 Global Sickle Cell Anemia Therapeutics Sales Value, by Application (%) (2020-2031)
5 Segmentation by Region
5.1 Global Sickle Cell Anemia Therapeutics Sales Value by Region
5.1.1 Global Sickle Cell Anemia Therapeutics Sales Value by Region: 2020 VS 2024 VS 2031
5.1.2 Global Sickle Cell Anemia Therapeutics Sales Value by Region (2020-2025)
5.1.3 Global Sickle Cell Anemia Therapeutics Sales Value by Region (2026-2031)
5.1.4 Global Sickle Cell Anemia Therapeutics Sales Value by Region (%), (2020-2031)
5.2 North America
5.2.1 North America Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
5.2.2 North America Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
5.3 Europe
5.3.1 Europe Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
5.3.2 Europe Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
5.4 Asia Pacific
5.4.1 Asia Pacific Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
5.4.2 Asia Pacific Sickle Cell Anemia Therapeutics Sales Value by Region (%), 2024 VS 2031
5.5 South America
5.5.1 South America Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
5.5.2 South America Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
5.6 Middle East & Africa
5.6.1 Middle East & Africa Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
5.6.2 Middle East & Africa Sickle Cell Anemia Therapeutics Sales Value by Country (%), 2024 VS 2031
6 Segmentation by Key Countries/Regions
6.1 Key Countries/Regions Sickle Cell Anemia Therapeutics Sales Value Growth Trends, 2020 VS 2024 VS 2031
6.2 Key Countries/Regions Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
6.3 United States
6.3.1 United States Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
6.3.2 United States Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
6.3.3 United States Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
6.4 Europe
6.4.1 Europe Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
6.4.2 Europe Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
6.4.3 Europe Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
6.5 China
6.5.1 China Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
6.5.2 China Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
6.5.3 China Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
6.6 Japan
6.6.1 Japan Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
6.6.2 Japan Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
6.6.3 Japan Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
6.7 South Korea
6.7.1 South Korea Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
6.7.2 South Korea Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
6.7.3 South Korea Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
6.8 Southeast Asia
6.8.1 Southeast Asia Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
6.8.2 Southeast Asia Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
6.8.3 Southeast Asia Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
6.9 India
6.9.1 India Sickle Cell Anemia Therapeutics Sales Value, 2020-2031
6.9.2 India Sickle Cell Anemia Therapeutics Sales Value by Type (%), 2024 VS 2031
6.9.3 India Sickle Cell Anemia Therapeutics Sales Value by Application, 2024 VS 2031
7 Company Profiles
7.1 Emmaus Medical
7.1.1 Emmaus Medical Profile
7.1.2 Emmaus Medical Main Business
7.1.3 Emmaus Medical Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.1.4 Emmaus Medical Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.1.5 Emmaus Medical Recent Developments
7.2 Theravia
7.2.1 Theravia Profile
7.2.2 Theravia Main Business
7.2.3 Theravia Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.2.4 Theravia Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.2.5 Theravia Recent Developments
7.3 Pfizer
7.3.1 Pfizer Profile
7.3.2 Pfizer Main Business
7.3.3 Pfizer Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.3.4 Pfizer Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.3.5 Pfizer Recent Developments
7.4 Novartis
7.4.1 Novartis Profile
7.4.2 Novartis Main Business
7.4.3 Novartis Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.4.4 Novartis Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.4.5 Novartis Recent Developments
7.5 Bluebird Bio
7.5.1 Bluebird Bio Profile
7.5.2 Bluebird Bio Main Business
7.5.3 Bluebird Bio Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.5.4 Bluebird Bio Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.5.5 Bluebird Bio Recent Developments
7.6 Novo Nordisk
7.6.1 Novo Nordisk Profile
7.6.2 Novo Nordisk Main Business
7.6.3 Novo Nordisk Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.6.4 Novo Nordisk Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.6.5 Novo Nordisk Recent Developments
7.7 Gamida Cell
7.7.1 Gamida Cell Profile
7.7.2 Gamida Cell Main Business
7.7.3 Gamida Cell Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.7.4 Gamida Cell Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.7.5 Gamida Cell Recent Developments
7.8 CRISPR Therapeutics
7.8.1 CRISPR Therapeutics Profile
7.8.2 CRISPR Therapeutics Main Business
7.8.3 CRISPR Therapeutics Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.8.4 CRISPR Therapeutics Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.8.5 CRISPR Therapeutics Recent Developments
7.9 GlycoMimetics
7.9.1 GlycoMimetics Profile
7.9.2 GlycoMimetics Main Business
7.9.3 GlycoMimetics Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.9.4 GlycoMimetics Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.9.5 GlycoMimetics Recent Developments
7.10 Prolong Pharmaceuticals
7.10.1 Prolong Pharmaceuticals Profile
7.10.2 Prolong Pharmaceuticals Main Business
7.10.3 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.10.4 Prolong Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.10.5 Prolong Pharmaceuticals Recent Developments
7.11 Modus Therapeutics
7.11.1 Modus Therapeutics Profile
7.11.2 Modus Therapeutics Main Business
7.11.3 Modus Therapeutics Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.11.4 Modus Therapeutics Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.11.5 Modus Therapeutics Recent Developments
7.12 Sangamo Biosciences
7.12.1 Sangamo Biosciences Profile
7.12.2 Sangamo Biosciences Main Business
7.12.3 Sangamo Biosciences Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.12.4 Sangamo Biosciences Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.12.5 Sangamo Biosciences Recent Developments
7.13 Bioverativ
7.13.1 Bioverativ Profile
7.13.2 Bioverativ Main Business
7.13.3 Bioverativ Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.13.4 Bioverativ Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.13.5 Bioverativ Recent Developments
7.14 Imara
7.14.1 Imara Profile
7.14.2 Imara Main Business
7.14.3 Imara Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.14.4 Imara Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.14.5 Imara Recent Developments
7.15 Ironwood Pharmaceuticals
7.15.1 Ironwood Pharmaceuticals Profile
7.15.2 Ironwood Pharmaceuticals Main Business
7.15.3 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Products, Services and Solutions
7.15.4 Ironwood Pharmaceuticals Sickle Cell Anemia Therapeutics Revenue (US$ Million) & (2020-2025)
7.15.5 Ironwood Pharmaceuticals Recent Developments
8 Industry Chain Analysis
8.1 Sickle Cell Anemia Therapeutics Industrial Chain
8.2 Sickle Cell Anemia Therapeutics Upstream Analysis
8.2.1 Key Raw Materials
8.2.2 Raw Materials Key Suppliers
8.2.3 Manufacturing Cost Structure
8.3 Midstream Analysis
8.4 Downstream Analysis (Customers Analysis)
8.5 Sales Model and Sales Channels
8.5.1 Sickle Cell Anemia Therapeutics Sales Model
8.5.2 Sales Channel
8.5.3 Sickle Cell Anemia Therapeutics Distributors
9 Research Findings and Conclusion
10 Appendix
10.1 Research Methodology
10.1.1 Methodology/Research Approach
10.1.1.1 Research Programs/Design
10.1.1.2 Market Size Estimation
10.1.1.3 Market Breakdown and Data Triangulation
10.1.2 Data Source
10.1.2.1 Secondary Sources
10.1.2.2 Primary Sources
10.2 Author Details
10.3 Disclaimer

Contact US

Ankit Jain - Director, Global Digital Marketing

QY Research, INC.
India Office -
315Work Avenue, Raheja Woods, Kalyani Nagar,
Pune, Maharashtra 411006, India
Web - https://www.qyresearch.in
Email- ankit@qyresearch.com

About US:

QYResearch is a leading global market research and consulting company established in 2007. With over 17 years' experience and professional research team in various cities over the world QY Research focuses on management consulting, database and seminar services, IPO consulting, industry chain research and customized research to help our clients in providing non-linear revenue model and make them successful. We are globally recognized for our expansive portfolio of services, good corporate citizenship, and our strong commitment to sustainability.

This release was published on openPR.